ecopipam

PARSIPPANY, N.J., August 19, 2026 Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its...

CHICAGO, Ill., May 26, 2026 Emalex Biosciences announced that Phase 3 clinical data for ecopipam, its investigational dopamine-1 (D1)...

PARSIPPANY, NEW JERSEY & CHICAGO, April 29, 2026 Teva Pharmaceutical Industries Ltd. has announced a definitive agreement to acquire...